Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 1;64(9):1283-1288.
doi: 10.1093/cid/cix129.

Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics

Timothy M Block  1 , Stephen Locarnini  2 , Brian J McMahon  3 , Barbara Rehermann  4 , Marion G Peters  5
Affiliations
Review

Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics

Timothy M Block et al. Clin Infect Dis. .

Abstract

New hepatitis B virus (HBV) therapies are expected to have breakthrough benefit for patients. HBV functional cure is sustained hepatitis B surface antigen loss and anti-HBs gain, with normalization of serum aminotransferases off therapy. Virologic or complete cure additionally includes loss of HBV covalently closed circular DNA. Currently available endpoints of therapy are inadequate to evaluate the efficacy of many of the new therapeutics. Therefore, either new ways of using the existing virologic endpoints and laboratory values or entirely new biomarkers are needed. In this review, we discuss the currently used endpoints, potential new endpoints, as well as what new markers are needed to assess the ability of HBV therapeutics to achieve functional and virologic cure in various phases of HBV infection. In addition, we discuss how patient selection from differing phases of HBV impacts the choice of HBV drug(s) needed to achieve cure.

Keywords: immunology; pathology; therapeutics; virology; markers.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Liang TJ, Block TM, McMahon BJ, et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatology 2015; 62:1893–908. - PMC - PubMed
    1. Revill P, Testoni B, Locarnini S, Zoulim F. Global strategies are required to cure and eliminate HBV infection. Nat Rev Gastroenterol Hepatol 2016; 13:239–48. - PubMed
    1. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis 2016; 14:381–96. - PubMed
    1. Gordon SC, Lamerato LE, Rupp LB, et al. ; CHeCS Investigators Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol 2014; 12:885–93. - PMC - PubMed
    1. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63:261–83. - PMC - PubMed